Secondary dyslipidemia: its treatments and association with atherosclerosis

被引:37
|
作者
Yanai, Hidekatsu [1 ]
Yoshida, Hiroshi [2 ]
机构
[1] Kohnodai Hosp, Dept Diabet Endocrinol & Metab, Natl Ctr Global Hlth & Med, 1-7-1 Kohnodai, Chiba 2728516, Japan
[2] Jikei Univ, Dept Lab Med, Kashiwa Hosp, Chiba, Japan
来源
GLOBAL HEALTH & MEDICINE | 2021年 / 3卷 / 01期
关键词
hypothyroidism; low-density lipoprotein; nephrotic syndrome; triglyceride;
D O I
10.35772/ghm.2020.01078
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Dyslipidemia is classified into primary and secondary types. Primary dyslipidemia is basically inherited and caused by single or multiple gene mutations that result in either overproduction or defective clearance of triglycerides and cholesterol. Secondary dyslipidemia is caused by unhealthy lifestyle factors and acquired medical conditions, including underlying diseases and applied drugs. Secondary dyslipidemia accounts for approximately 30-40% of all dyslipidemia. Secondary dyslipidemia should be treated by finding and addressing its causative diseases or drugs. For example, treatment of secondary dyslipidemia, such as hyperlipidemia due to hypothyroidism, by using statin without controlling hypothyroidism, may lead to myopathy and serious adverse events such as rhabdomyolysis. Differential diagnosis of secondary dyslipidemia is very important for safe and effective treatment. Here, we describe an overview about diseases and drugs that interfere with lipid metabolism leading to secondary dyslipidemia. Further, we show the association of each secondary dyslipidemia with atherosclerosis and the treatments for such dyslipidemia.
引用
收藏
页码:15 / 23
页数:9
相关论文
共 50 条
  • [31] Zebrafish Models for Dyslipidemia and Atherosclerosis Research
    Schlegel, Amnon
    FRONTIERS IN ENDOCRINOLOGY, 2016, 7
  • [32] Chronic Kidney Disease, Dyslipidemia, and Atherosclerosis
    Shoji, Tetsuo
    Abe, Takaaki
    Matsuo, Hiroshi
    Egusa, Genshi
    Yamasaki, Yoshimitsu
    Kashihara, Naoki
    Shirai, Kohji
    Kashiwagi, Atsunori
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2012, 19 (04) : 299 - 315
  • [33] DYSLIPIDEMIA REGISTRY OF THE SPANISH ATHEROSCLEROSIS SOCIETY
    Perez-Calahorra, S.
    Lahoz, C.
    Plana, N.
    Errasti-Amiano, U.
    Climent, E.
    Elias Sanchez, T.
    Puzo, J.
    Zabala, S.
    Mateo-Gallego, R.
    Ros, E.
    Civeira, F.
    ATHEROSCLEROSIS, 2014, 235 (02) : E199 - E199
  • [34] Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
    Yanai, Hidekatsu
    Adachi, Hiroki
    Hakoshima, Mariko
    Iida, Sakura
    Katsuyama, Hisayuki
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (20)
  • [35] Dyslipidemia differentially mediates the association between hepatic steatosis and calcified atherosclerosis in different vascular beds
    Phillips, Jonathan
    Allison, Matthew A.
    Wright, C. Michael
    CIRCULATION, 2007, 115 (08) : E284 - E284
  • [36] ASSOCIATION OF DYSLIPIDEMIA, HYPERTENSION AND CHRONIC KIDNEY DISEASES WITH CAROTID ATHEROSCLEROSIS IN PATIENTS WITH TYPE 2 DIABETES
    Vasilkova, Volha
    Mokhort, Tatiana
    Naumenko, Elena
    Zmailik, Margarita
    JOURNAL OF HYPERTENSION, 2016, 34 : E110 - E110
  • [37] Association of hypertension, type 2 diabetes mellitus and dyslipidemia with the duration of inpatient treatments and recurrence of schizophrenia*
    Lamade, Eva Kathrin
    Oezer, Nicole
    Schaupp, Bernhard
    Krumm, Bertram
    Deuschle, Michael
    Haefner, Sibylle
    JOURNAL OF PSYCHOSOMATIC RESEARCH, 2023, 172
  • [38] Morphology and its Concepts in Secondary Education: Common Treatments
    Saragossa, Abelard
    TEJUELO-DIDACTICA DE LA LENGUA Y LA LITERATURA, 2015, 22 (01): : 168 - 189
  • [39] Prevalence of dyslipidemia and its association with insomnia in a community based population in China
    Yiqiang Zhan
    Fen Zhang
    Leihong Lu
    Jinsong Wang
    Yihong Sun
    Rongjing Ding
    Dayi Hu
    Jinming Yu
    BMC Public Health, 14
  • [40] Prevalence of dyslipidemia and its association with opium consumption in the Rafsanjan cohort study
    Jamali, Zahra
    Karimabad, Mojgan Noroozi
    Khalili, Parvin
    Sadeghi, Tabandeh
    Sayadi, Ahmadreza
    Rostamabadi, Faegheh Mohammadakbari
    La Vecchia, Carlo
    Esmaeili-Nadimi, Ali
    SCIENTIFIC REPORTS, 2022, 12 (01)